RP-HPLC raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-19 and is reviewed periodically as new material appears.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Usually the largest workers in the colony develop into repletes; and, if repletes are removed from the colony, other workers become repletes, demonstrating the flexibility of this particular polymorphism. This polymorphism in morphology and behaviour of workers initially was thought to be determined by environmental factors such as nutrition and hormones that led to different developmental paths; however, genetic differences between worker castes have been noted in Acromyrmex sp. These polymorphisms are caused by relatively small genetic changes; differences in a single gene of Solenopsis invicta can decide whether the colony will have single or multiple queens. The Australian jack jumper ant (Myrmecia pilosula) has only a single pair of chromosomes (with the males having just one chromosome as they are haploid), the lowest number known for any animal, making it an interesting subject for studies in the genetics and developmental biology of social insects.
== Preparation of azide == The aforementioned conversion to acyl azide has been carried out multifariously; Bergmann utilized methyl ester and hydrazide, whereas more recent attempts have designed methods such as: nitrosylation of N-formylaminoacyl hydrazide and subsequent substitution by sodium azide, reaction of a carboxylic acid with diphenyl phosphorazidate, triethylamine, and a hydroxyl component, and reaction between TMS azide and the anhydride of an amino acid.
will lead to a dimension-different PseAA composition. Using Eq.6 is just one of the many modes for deriving the correlation factors in PseAAC or its components. The others, such as the physicochemical distance mode and amphiphilic pattern mode, can also be used to derive different types of PseAAC, as summarized in a 2009 review article. In 2011, the formulation of PseAAC (Eq.3) was extended to a form of the general PseAAC as given by:
== External links == International Chemical Safety Card 0104 National Pollutant Inventory – Polycyclic Aromatic Hydrocarbon Fact Sheet "Lung cancer as consequence by Benzopyrene in smokers". Lung Cancer. Archived from the original on April 14, 2005. Retrieved March 5, 2005. "Levels of Benzopyrene in Burnt toasts". Guardian Unlimited, Special reports: Close encounters. Retrieved March 5, 2005. Karle, I. L. (2004). "Crystal and molecular structure of a benzo[a]pyrene-7,8-diol-9,10-epoxide N2-deoxyguanosine adduct: Absolute configuration and conformation". Proceedings of the National Academy of Sciences. 101 (6): 1433–1438. Bibcode:2004PNAS..101.1433K. doi:10.1073/pnas.0307305101. PMC 341736. PMID 14757823.
Sources: en.wikipedia.org
==== Absorption and metabolism ==== Morphine can be taken orally, sublingually, bucally, rectally, subcutaneously, intranasally, intravenously, intrathecally or epidurally and inhaled via a nebulizer. As a recreational drug, it is becoming more common to inhale ("Chasing the Dragon"), but, for medical purposes, intravenous (IV) injection is the most common method of administration. Morphine is subject to extensive first-pass metabolism (a large proportion is broken down in the liver), so, if taken orally, only 40% to 50% of the dose reaches the central nervous system. Resultant plasma levels after subcutaneous (SC), intramuscular (IM), and IV injection are all comparable. After IM or SC injections, morphine plasma levels peak in approximately 20 min, and, after oral administration, levels peak in approximately 30 min. Morphine is metabolised primarily in the liver and approximately 87% of a dose of morphine is excreted in the urine within 72 h of administration. Morphine is metabolized primarily into morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) via glucuronidation by phase II metabolism enzyme UDP-glucuronosyl transferase-2B7 (UGT2B7). About 60% of morphine is converted to M3G, and 6% to 10% is converted to M6G. Not only does the metabolism occur in the liver but it may also take place in the brain and the kidneys. M3G does not undergo opioid receptor binding and has no analgesic effect. M6G binds to μ-receptors and is half as potent an analgesic as morphine in humans.
Clinical and Vaccine Immunology (CVI) was a peer-reviewed journal published by the American Society for Microbiology. CVI enhances our understanding of the immune response in health and disease by showcasing important clinically relevant research, including new animal models for human immunologic diseases, viral immunology, immunopathogenesis, and clinical laboratory immunology. In particular, the journal highlights important discoveries in immunization and vaccine research, such as the development and evaluation of vaccines, human and animal immune responses to vaccines, vaccine vectors, adjuvants and immunomodulators, quantitative assays of vaccine efficacy, and clinical trials. The journal publishes primary research articles, editorials, commentaries, minireviews, and case reports. Articles are freely accessible after six months (delayed open access). Through its "Global Outreach Program", free online access is available to qualified microbiologists in eligible developing countries.
== Applications == Chemical synthesis plays a crucial role across various industries, enabling the development of materials, medicines, and technologies with significant real-world impacts. Catalysis: The development of catalysts is vital for numerous industrial processes, including petroleum refining, petrochemical production, and pollution control. Catalysts synthesized through chemical processes enhance the efficiency and sustainability of these operations. Medicine: Organic synthesis plays a vital role in drug discovery, allowing chemists to develop and optimize new drugs by modifying organic molecules. Additionally, the synthesis of metal complexes for medical imaging and cancer treatments is a key application of chemical synthesis, enabling advanced diagnostic and therapeutic techniques. Biopharmaceuticals: Chemical synthesis is critical in the production of biopharmaceuticals, including monoclonal antibodies and other biologics. Chemical synthesis enables the creation and modification of organic and biologically sourced compounds used in these treatments. Advanced techniques, such as DNA recombinant technology and cell fusion, rely on chemical synthesis to produce biologics tailored for specific diseases, ensuring they work effectively and target diseases precisely.
The risk of experiencing severe withdrawal symptoms is high if a patient has become physically dependent and discontinues oxycodone abruptly. Medically, when the drug has been taken regularly over an extended period, it is withdrawn gradually rather than abruptly. People who regularly use oxycodone recreationally or at higher than prescribed doses are at even higher risk of severe withdrawal symptoms. The symptoms of oxycodone withdrawal, as with other opioids, may include "anxiety, panic attack, nausea, insomnia, muscle pain, muscle weakness, fevers, and other flu-like symptoms". Withdrawal symptoms have also been reported in newborns whose mothers had been either injecting or orally taking oxycodone during pregnancy.
The theatre in Brazil has its origins in the period of Jesuit expansion, when theater was used for the dissemination of Catholic doctrine in the 16th century. In the 17th and 18th centuries, dramatists on the scene of European derivation were for court or private performances. During the 19th century, the playwrights Antônio Gonçalves Dias and Luís Carlos Martins Pena were known for their performance. There were also numerous operas and orchestras. The Brazilian conductor Antônio Carlos Gomes became internationally known with operas such as Il Guarany. At the end of the 19th century, orchestrated dramaturgias were accompanied with songs of famous artists such as the conductress Chiquinha Gonzaga. Already in the early 20th century there was the presence of theaters, entrepreneurs and actor companies. In 1940, Paschoal Carlos Magno and his student's theater, the comedians group and the Italian actors Adolfo Celi, Ruggero Jacobbi and Aldo Calvo, founders of the Teatro Brasileiro de Comédia, renewed the Brazilian theater. From the 1960s, it was attended by a theater dedicated to social and religious issues. The most prominent authors at this stage were Jorge Andrade and Ariano Suassuna.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.